Theranostics

On this page

Introduction - See & Treat Magic

  • Theranostics: A paradigm combining diagnostics (Dx) and therapy (Tx) using a single agent or platform.
  • Core Principle: "See what you treat, treat what you see."
    • Diagnostic component visualizes the target (e.g., tumor, receptor).
    • Therapeutic component delivers treatment to the visualized target.
  • Mechanism: Utilizes molecules that can be labeled with either an imaging isotope (for Dx) or a therapeutic isotope/drug (for Tx).
    • Often involves a targeting moiety (e.g., peptide, antibody) linked to a radionuclide.

Theranostics for hematologic malignancies

  • Goal: Personalized medicine - precise localization and targeted treatment, minimizing systemic toxicity.

⭐ Theranostics embodies the 'magic bullet' concept envisioned by Paul Ehrlich, aiming for highly specific drug delivery to diseased cells.

  • Key advantage: Allows for patient selection, treatment planning, and monitoring response effectively.

Radiopharmaceutical Pairs - Dynamic Duos

Theranostics employs 'dynamic duos': a diagnostic radiopharmaceutical to visualize a target, and a therapeutic counterpart to treat it. Both agents bind to the same molecular entity. These pairs enable personalized medicine by confirming target presence before therapy.

📌 Iodine ($^{123}I$/$^{131}I$): Imaging and Internal radiotherapy for thyroid.

Diagnostic PartnerTherapeutic PartnerMolecular TargetPrimary Clinical Use(s)
$^{68}Ga$-DOTATATE/-NOC/-TOC$^{177}Lu$-DOTATATE, $^{90}Y$-DOTATOCSSTRNeuroendocrine Tumors (NETs)
$^{68}Ga$-PSMA-11/-I&T$^{177}Lu$-PSMA-617, $^{225}Ac$-PSMAPSMAProstate Cancer
$^{123}I$ or $^{131}I$ (low dose)$^{131}I$ (high dose)NIS (Sodium-Iodide Symporter)Differentiated Thyroid Cancer (DTC)
$^{99m}Tc$-MDP/HMDP$^{153}Sm$-EDTMP, $^{223}RaCl_2$Hydroxyapatite (Bone)Painful Bone Metastases
$^{111}In$-Pentetreotide$^{90}Y$-DOTATOC, $^{177}Lu$-DOTATATESSTRNETs (SPECT option/therapy)

Key Clinical Uses - Cancer Combat Zones

  • Prostate Cancer (PCa):

    • Target: Prostate-Specific Membrane Antigen (PSMA).
    • Diagnostic: $^{68}Ga$-PSMA PET/CT (staging, recurrence).
    • Therapeutic: $^{177}Lu$-PSMA (metastatic Castration-Resistant PCa, mCRPC).
    • Threshold: High PSMA expression on PET.

    ⭐ $^{177}Lu$-PSMA therapy shows significant survival benefits in mCRPC patients post prior therapy failure. PSMA PET/CT before and after Lu-177 PSMA therapy

  • Neuroendocrine Tumors (NETs):

    • Target: Somatostatin Receptors (SSTRs).
    • Diagnostic: $^{68}Ga$-DOTATATE/TOC PET/CT.
    • Therapeutic: Peptide Receptor Radionuclide Therapy (PRRT) with $^{177}Lu$-DOTATATE / $^{90}Y$-DOTATATE.
    • 📌 Mnemonic: 'DOTATATE targets SSTRs - Don't Hesitate, Radiate!'
    • Key: High SSTR expression; Ki-67 < 20% often preferred for PRRT.
  • Differentiated Thyroid Cancer (DTC):

    • Target: Sodium-Iodide Symporter (NIS).
    • Diagnostic: $^{123}I$ or low-dose $^{131}I$ Whole Body Scan (WBS).
    • Therapeutic: High-dose $^{131}I$ (remnant ablation, metastatic disease).
  • Flowchart: PSMA Therapy Selection for mCRPC

Dosimetry & Future - Scan, Plan, Advance!

  • Dosimetry:
    • Calculates absorbed radiation dose (Gy) for personalized theranostics.
    • Utilizes imaging (SPECT/CT, PET/CT) & MIRD schema.
    • Optimizes tumor dose vs. normal tissue toxicity.
  • Future Horizons:
    • Alpha-emitters ($^{225}Ac$, $^{213}Bi$): High LET, short-range for potent, localized kill.
    • New radiopharmaceuticals & targets.
    • AI in planning & response prediction.
    • Combination therapies (e.g., immunotherapy).

⭐ Alpha-emitters like $^{225}Ac$ are highly promising due to their high Linear Energy Transfer (LET) and short path length, delivering potent, localized cytotoxicity with minimal damage to surrounding healthy tissue. Alpha vs Beta Emitter Mechanism in Theranosticsoka

High‑Yield Points - ⚡ Biggest Takeaways

  • Theranostics uniquely combines diagnostic imaging and targeted radionuclide therapy.
  • Core concept: "See what you treat, treat what you see", enabling personalized treatment.
  • Lu-177 DOTATATE is pivotal for imaging and treating neuroendocrine tumors (NETs).
  • Lu-177 PSMA targets prostate-specific membrane antigen (PSMA) in advanced prostate cancer.
  • I-131 remains a cornerstone for both diagnosis and therapy of thyroid disorders.
  • Radium-223 (Xofigo), an alpha-emitter, is used for bone metastases in prostate cancer.
  • Enables patient-specific treatment selection and monitoring of therapeutic response.

Practice Questions: Theranostics

Test your understanding with these related questions

Cardiotoxicity caused by radiotherapy & chemotherapy is best detected by

1 of 5

Flashcards: Theranostics

1/3

C11 Methionine PET is done for the _____

TAP TO REVEAL ANSWER

C11 Methionine PET is done for the _____

brain tumor.

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial